🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 10 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/02/2014 119,68 120,50 116,47 116,75 -1,85% 3,37% 5.046.200
31/01/2014 118,55 120,21 118,10 118,95 -1,60% 1,78% 4.934.900
30/01/2014 120,07 121,98 119,55 120,89 +1,44% 2,02% 3.321.100
29/01/2014 117,00 121,16 117,00 119,17 -1,27% 3,56% 5.730.400
28/01/2014 118,39 121,87 118,31 120,70 +1,84% 3,01% 4.348.600
27/01/2014 119,25 119,83 117,42 118,52 -0,65% 2,02% 4.125.400
24/01/2014 122,61 122,61 118,99 119,29 -3,49% 2,95% 4.992.900
23/01/2014 123,00 124,22 121,60 123,60 -0,62% 2,13% 3.534.800
22/01/2014 119,83 124,46 119,58 124,37 +4,29% 4,07% 5.086.200
21/01/2014 119,96 120,00 118,57 119,25 +0,08% 1,19% 3.072.700
17/01/2014 118,91 119,55 118,31 119,15 +0,10% 1,04% 4.010.000
16/01/2014 118,82 119,69 118,21 119,03 +0,44% 1,25% 2.553.200
15/01/2014 118,42 118,95 117,40 118,51 +0,67% 1,31% 3.064.600
14/01/2014 116,84 117,94 116,22 117,72 +1,13% 1,47% 2.541.200
13/01/2014 118,32 118,73 115,94 116,40 -1,35% 2,36% 3.703.900
10/01/2014 119,00 119,00 116,20 117,99 -0,76% 2,35% 3.053.100
09/01/2014 116,54 118,96 116,22 118,89 +2,60% 2,35% 3.400.000
08/01/2014 116,64 116,90 115,35 115,88 -0,47% 1,33% 2.481.800
07/01/2014 113,50 116,79 113,27 116,43 +2,60% 3,10% 3.632.400
06/01/2014 114,47 114,92 113,12 113,48 -0,86% 1,57% 2.838.100
03/01/2014 115,70 115,97 114,06 114,47 -1,15% 1,65% 2.075.800
02/01/2014 114,36 116,19 114,06 115,80 +1,51% 1,86% 2.528.800
31/12/2013 115,91 115,95 113,67 114,08 -1,22% 1,97% 2.362.700
30/12/2013 115,36 115,52 114,39 115,49 +0,32% 0,98% 1.534.000
27/12/2013 114,89 115,49 114,36 115,12 +0,66% 0,98% 2.038.700
26/12/2013 112,62 114,48 112,45 114,36 +1,88% 1,80% 1.558.500
24/12/2013 113,34 113,41 112,20 112,25 -0,84% 1,07% 1.013.500
23/12/2013 114,67 114,72 112,52 113,20 -0,73% 1,92% 2.156.800
20/12/2013 112,40 114,98 112,02 114,03 +1,27% 2,63% 5.285.600
19/12/2013 112,55 112,69 110,92 112,60 -0,12% 1,57% 2.802.600